Sangamo Therapeutics and Pfizer announced updated results from the Phase 1/2 Alta Study evaluating investigational SB-525 gene therapy for severe hemophilia A. The data reveals that SB-525 was generally well tolerated and demonstrated a dose-dependent increase in...